Swine flu basket

As some readers have pointed out, a few years ago we did very well with a basket of bird flu stocks during the worldwide bird flu threat. The difference this time is that swine flu is more of a fact then a threat. The link above to my March, 2006 post listing all the stocks in the bird flu basket is one source of ideas for swine flu stocks. I've taken just three of those stocks to put in the swine flu basket, focusing on what I believe are the three single best ideas. These stocks, among others, are low priced and all have the real potential for triple digit returns in the tumultuous times ahead.

NanoViricides

You all know by now my first pick, NNVC, it is perhaps the only one that you need as it is placed in a sweet spot of treatment, they don't produce vaccines, they produce functional cures.



Above is a one year Weekly chart of NNVC. As I wrote yesterday at the Anti-Cramer site, this stock is pennies away from a major break-out. I expect it to open well above the $0.83 break-out level on Monday.

Novavax

The second stock for consideration is NVAX. This stock treated us very well as part of the avian flu basket of stocks and based on Friday's price action, just shy of a double in one day, it is already running:


NVAX was an $8 stock at the height of the bird flu run, a $16 dollar stock in 2002. One or both of these former high levels could get taken out.

Sinovac Biotech

Below is a description, then a chart of the third swine flu basket stock, SVA.

Sinovac Biotech, Ltd., a biopharmaceutical company, through its subsidiaries, engages in the research, development, production, and sale of vaccines that protect against human infectious diseases primarily in the People's Republic of China. It offers Healive, a vaccine for hepatitis A; Bilive, a combined hepatitis A and B vaccine; and Anflu, a split virus influenza vaccine. The company also develops vaccines for the H5N1 strain of pandemic influenza virus that are in Phase I and Phase II clinical trials; a vaccine for the Japanese encephalitis virus, which is in pre-clinical development stage; and a vaccine for the SARS virus that has completed a Phase I clinical trial. Sinovac Biotech markets and sells its vaccine products primarily through various provincial and municipal centers for disease control. The company was founded in 1999 and is headquartered in Beijing, the People's Republic of China.

During the bird flu scare, SVA hit $9.50. The EW chart above is suggesting $3.50 for its initial run, but that could wind up being only Wave 1 of a Primary degree five wave advance, taking out it's old high.


You are welcome to add to this basket of three stocks any stocks that you think belong. If you do, feel free to share your ideas in Comments. Please keep in mind that during the 2005-2006 bird flu scare, the stock market was still in a major up phase. This time is different, the market is in a major down phase. I would be much more aggressive in taking profits on partial positions as these stocks pop with the news.


A